Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
Corticosteroid-sparing effect in patients with moderately to severely active ulcerative colitis treated with mirikizumab maintenance therapy
book_2
Source:
UEG Week 2023 - Poster session
calendar_today
Published on Medfyle:
November 2023
In this medfyle
Corticosteroid-free remission is a treatment goal for patients with UC. Mirikizumab has already demonstrated efficacy in moderately to severely active UC and new analyses from the LUCENT-2 maintenance trial of mirikizumab treatment in UC suggest that it also has a clinically meaningful corticosteroid-sparing effect.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
